摘要
目的探讨帕立骨化醇对血透后继发性甲状旁腺功能亢进(SHPT)患者血清钙、磷水平以及骨痛情况的影响。方法选取2019年1月至2020年10月我院收治的70例血透后SHPT患者,依据随机数字表法将其分为对照组(n=35)和观察组(n=35)。结果治疗12周后,两组患者的血清钙水平升高,血清磷水平降低,且观察组的变化更显著;两组VAS评分降低,观察组更低;且观察组不良反应发生率更低,差异有统计学意义(P<0.05)。结论将帕立骨化醇应用在血透后SHPT患者中,可改善患者的血清钙、磷水平及骨痛程度,且安全性更高。
Objective This paper aims to explore the effect of paricalcitol on serum calcium and phosphorus levels and bone pain in patients with secondary hyperparathyroidism(SHPT)after hemodialysis.Methods 70 patients with SHPT after hemodialysis treated in this hospital from January 2019 to October 2020 were selected,which were divided into a control group(n=35)and an observation group(n=35).Results 12 weeks after treatment,levels of serum calcium and phosphorus in the two groups increased,and the changes in the observation group were more significant.The VAS score of the two groups decreased,and the score of the observation group was lower,and the incidence of adverse reactions in the observation group was lower,the difference was statistically significant(P<0.05).Conclusion The application of paricalcitol in SHPT patients after hemodialysis can improve the serum calcium and phosphorus levels and the degree of bone pain in patients,which has higher safety.
作者
吴雅莉
朱雯
WU Ya-li;ZHU Wen(Department of Nephrology,the Second People's Hospital of Jingdezhen,Jingdezhen Jiangxi 333000,China)
出处
《透析与人工器官》
2021年第2期15-16,46,共3页
Chinese Journal of Dialysis and Artificial Organs
作者简介
吴雅莉(1983-),女,大学本科,主治医师。从事肾内科临床工作;通信作者:朱雯,E-mail:597060221@qq.com
